Skip to main content
XLO logo

XLO · Xilio Therapeutics, Inc. · Holdings

Track XLO — free
$7.99 -0.02 (-0.25%)
Market Cap
$44.47M
Shares
5.78M
Volume · Oct 28 2923 Avg daily vol (3M) 12.97K

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Some SEC filings for this period have not finished importing. Holder totals and changes may be incomplete; these filings remain queued for recovery.
Holders: 27
Total Value: $32,641,942
Total Shares: 3,407,302

Institutional Ownership Trend

19 quarters

Holder Concentration

Across 27 13F filers · Δ vs Mar 31, 2026
Top Holder
19.5%
Sep 2023 → Jun 2026 · range 17.1% – 41.3%
−5.9 pts
Top 5
75.0%
Sep 2023 → Jun 2026 · range 65.3% – 81.1%
−1.9 pts
Top 10
93.0%
Sep 2023 → Jun 2026 · range 89.6% – 95.8%
+1.3 pts
HHI
1,322
Sep 2023 → Jun 2026 · range 1,108 – 2,298
Broadly held−313

Who Holds XLO

Last 8 quarters through Jun 30, 2026

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Jun 30, 2026: 27 filers, like-for-like change +32.7%; actively managed books +33.8%; index-like books +22.7%.

Holder type Share Filers Change
Registered adviser 50.8% 15 +102.7%
Adviser 4.5% 1 0.0%
Bank 0.4% 3 -24.0%
Holding company 1.9% 2 -30.1%
Broker-dealer 0.0% 0 —
Non-US 0.0% 0 —
Exempt adviser 0.0% 0 —
Unknown 42.4% 6 -0.4%
How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Excluded 2 holders with no observed 2026-06-30 13F.

Conviction and Crowding

27 13F filers, quarter ended Jun 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
1
3.70% of filers hold it in their top 10
Mar 31, 2026: 3
Holders above 5%
0
median weight 0.001%
Mar 31, 2026: 1
Crowding
28.8%
of shares outstanding, 79th percentile
Mar 31, 2026: 14.6%
Private-fund advisers
26.2%
of shares outstanding
Institutional ownership
58.9%
59.3% of the estimated free float
Top 10 holders
93.0%
of 13F shares, Herfindahl 0.132
Active holders
+33.8%
like-for-like share change of active filers
5% stakes on record
9
0 13D, 9 13G (4 institutional, 6 passive, 0 exempt)
How long holders have held it value-weighted 7.3 quarters
Under 1 year 53.2% 1 to 3 years 22.2% 3 years or more 24.6% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net buyers of $0 (0 buying, 0 selling).

Estimated Holder Cost Basis

Quarter ended Jun 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$9.63
estimated per share
Mar 31, 2026: $23.06
Quarter-end price
$9.58
implied by 13F values
Estimated gain or loss
-0.5%
price against the estimated cost
Estimated at a loss
45.2%
of costed 13F value

Estimated cost covers 41.9% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies XLO's active holders also own, quarter ended Jun 30, 2026
# Company Shared holders
1 TARA Protara Therapeutics, Inc. 3
2 ANTX AN2 Therapeutics, Inc. 3
3 UPB Upstream Bio, Inc. 3
4 STRO Sutro Biopharma, Inc. 3
5 CRBP Corbus Pharmaceuticals Holdings, Inc. 3
6 OVID Ovid Therapeutics Inc. 3
7 SVRA Savara Inc 4
8 HELP Helus Pharma Inc. 3
9 IRON Disc Medicine, Inc. 3
10 DNTH Dianthus Therapeutics, Inc. 3

Shareholder Targets

13F filers that own its peers but not XLO, quarter ended Jun 30, 2026

Found through its holder-overlap peers: TARA, ANTX, UPB, STRO, CRBP, OVID, SVRA, HELP, IRON, DNTH. 489 filers in all.

# Filer In peers
1 FMR LLC Holding company, Diversified active $1,215,362,305 9 held
2 WELLINGTON MANAGEMENT GROUP LLP Holding company, Diversified active $462,334,128 7 held
3 PRICE T ROWE ASSOCIATES INC /MD/ Registered adviser, Diversified active $384,581,573 9 held
4 T. Rowe Price Investment Management, Inc. Adviser, Diversified active $379,046,690 1 held
5 TCG Crossover Management, LLC Unknown, Diversified active $337,732,275 3 held
6 Fairmount Funds Management LLC Registered adviser, Concentrated $247,325,378 1 held
7 DEERFIELD MANAGEMENT COMPANY, L.P. Registered adviser, Concentrated $241,333,531 3 held
8 Venrock Adviser, LLC Registered adviser, Concentrated $231,320,840 3 held
9 RA CAPITAL MANAGEMENT, L.P. Registered adviser, Concentrated $207,456,766 2 held
10 Avidity Partners Management LP Registered adviser, Concentrated $205,423,856 2 held

Fund Ownership of XLO by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 3.83% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 0.61% 35,053
Index ETFs 3.22% 186,265
Active ETFs 0.00% 0
Active funds 0.31% 18,085
Unclassified 0.00% 0
All registered funds 4.14% 239,403
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Quarterly Activity

vs Mar 31, 2026
New
11
Increased
4
Decreased
4
Sold Out
6
Unchanged
8

New and Sold Out count only filers that reported a 13F for both quarters: a first-time filer's book is not a buy, and a fund that has not filed, or withheld its positions under confidential treatment, has not sold.

Holder count: +3
Institutional value: +48.2%
Shares held: +30.1%

Top Buyers

vs Mar 31, 2026
Institution Added Now Holds Open

Top Sellers

vs Mar 31, 2026
Institution Sold Now Holds Open

Top New Positions

vs Mar 31, 2026
Institution Acquired Value (USD) Open

Top Sold-Out Positions

vs Mar 31, 2026
Institution Previously Held Last Value (USD) Open
Showing 27 of 27
Export CSV
Holder Value (USD) % of 13F Shares Open
Key facts CIK 1840233 CUSIP 98422T209 Visit website Investor relations